electroCore, Inc. (NASDAQ:ECOR) Director Carrie Smith Cox bought 3,700 shares of the business’s stock in a transaction on Friday, August 17th. The shares were acquired at an average cost of $13.76 per share, for a total transaction of $50,912.00. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

NASDAQ ECOR traded up $0.29 during trading on Monday, reaching $13.85. 44,800 shares of the company’s stock traded hands, compared to its average volume of 89,412. electroCore, Inc. has a 12-month low of $12.85 and a 12-month high of $20.25.

electroCore (NASDAQ:ECOR) last posted its earnings results on Monday, August 13th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.17. The business had revenue of $0.39 million for the quarter.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. purchased a new position in shares of electroCore in the 2nd quarter worth approximately $206,000. Citadel Advisors LLC purchased a new position in shares of electroCore in the 2nd quarter worth approximately $427,000. Dean Capital Investments Management LLC purchased a new position in shares of electroCore in the 2nd quarter worth approximately $499,000. Millennium Management LLC purchased a new position in shares of electroCore in the 2nd quarter worth approximately $724,000. Finally, Sio Capital Management LLC purchased a new position in shares of electroCore in the 2nd quarter worth approximately $3,523,000. 2.15% of the stock is currently owned by institutional investors and hedge funds.

A number of research analysts have commented on ECOR shares. JMP Securities started coverage on shares of electroCore in a research report on Tuesday, July 17th. They set an “outperform” rating and a $23.00 target price on the stock. BTIG Research started coverage on shares of electroCore in a research report on Tuesday, July 17th. They set a “buy” rating and a $20.00 target price on the stock.

About electroCore

electroCore, LLC, a bioelectronic medicine company, engages in developing a range of patient-administered non-invasive vagus nerve stimulation therapies for the treatment of various conditions in neurology, rheumatology, and other fields. It is developing gammaCore, a prescription-only vagus nerve stimulation therapy, for the acute treatment of pain associated with migraine and episodic cluster headache in adults.

Further Reading: NASDAQ Stock Market Explained

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.